RxDoctor Payments Data

Dawn Nissen

Nurse Practitioner · Green Bay, WINPI 1487676979

Payments from drug & device makers

$2,265in general payments, 2019–2025

Across 16 payments — averaging $141.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • E.r. Squibb & Sons, L.L.C.$211
  • Baxter Healthcare$171
  • Medtronic$134
  • Haemonetics Corporation$98
  • Pfizer$93
  • plus $66 from 2 others

What the payments were for

  • Travel & lodging$85938%
  • Food & beverage$1,40762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Edwards Lifesciences7$1,494
E.r. Squibb & Sons, L.L.C.2$211
Baxter Healthcare1$171
Medtronic1$134
Haemonetics Corporation1$98
Pfizer1$93
Novartis2$52
True North Surgical Inc1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,265 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$18,757
Medicare patients
116
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$51,457
JardianceEmpagliflozin33$46,019
EntrestoSacubitril/Valsartan12$9,672
Metoprolol Succinate311$3,958
Potassium Chloride132$3,392
ClopidogrelClopidogrel Bisulfate181$2,411
Bumetanide51$1,171
Furosemide195$1,129
Midodrine Hcl11$1,066
Lisinopril119$829
Albuterol Sulfate HfaAlbuterol Sulfate16$757
Atorvastatin Calcium69$664
Spironolactone42$620
Losartan Potassium54$478
Amoxicillin155$462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$93$51,45757 claims
NovartisEntresto$52$9,67212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →